Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 87.37M | 196.49M | 298.76M | 398.00M | 380.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.37M | 196.49M | 298.76M | 398.00M | 380.79M |
| Cost of Revenue | 228.72M | 296.30M | 273.31M | 277.17M | 153.63M |
| Gross Profit | -141.35M | -99.82M | 25.45M | 120.83M | 227.16M |
| SG&A Expenses | 114.33M | 149.48M | 180.37M | 202.11M | 188.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 22.85M | 22.85M | 22.85M | -- | -- |
| Total Operating Expenses | 402.10M | 468.63M | 476.52M | 479.28M | 341.98M |
| Operating Income | -314.73M | -272.14M | -177.76M | -81.28M | 38.80M |
| Income Before Tax | -302.14M | -257.48M | -162.36M | -65.66M | 54.30M |
| Income Tax Expenses | -393.00K | 1.99M | 3.51M | 5.44M | 5.03M |
| Earnings from Continuing Operations | -301.74 | -259.47 | -165.87 | -71.10 | 49.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -301.74M | -259.47M | -165.87M | -71.10M | 49.27M |
| EBIT | -314.73M | -272.14M | -177.76M | -81.28M | 38.80M |
| EBITDA | -313.83M | -271.10M | -176.64M | -80.08M | 39.89M |
| EPS Basic | -4.43 | -3.82 | -2.44 | -1.04 | 0.73 |
| Normalized Basic EPS | -2.87 | -2.46 | -1.58 | -0.69 | 0.41 |
| EPS Diluted | -4.44 | -3.82 | -2.45 | -1.07 | 0.70 |
| Normalized Diluted EPS | -2.87 | -2.46 | -1.59 | -0.71 | 0.40 |
| Average Basic Shares Outstanding | 272.56M | 271.39M | 270.71M | 269.92M | 268.78M |
| Average Diluted Shares Outstanding | 272.56M | 273.17M | 274.82M | 276.93M | 279.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
